C4 Therapeutics (CCCC) Corporate presentation summary

Clinical pipeline and development strategy

• Advancing two clinical degraders: cemsidomide for multiple myeloma (MM) and CFT8919 for non-small cell lung cancer (NSCLC), with a focus on best-in-class and first-in-class opportunities.

• Cemsidomide is in Phase 2 (MOMENTUM trial) for 4L+ MM and Phase 1b in combination with elranatamab for 2L+ MM, aiming for accelerated approvals.

• CFT8919 targets EGFR L858R mutations in NSCLC, showing selectivity and activity in preclinical models, including brain metastasis.

• Discovery strategy now emphasizes inflammation, neuroinflammation, and neurodegeneration (INN) with a pipeline of degraders targeting validated pathways.

• Cash runway is projected through the end of 2028, supporting execution beyond key value inflection points.

Cemsidomide clinical and market potential

• Demonstrated compelling anti-myeloma activity and a differentiated safety profile in Phase 1, with 53% ORR at the highest dose and minimal dose discontinuations.

• Positioned for accelerated approval in both 2L+ and 4L+ MM, with a potential $2.5–$4B peak revenue opportunity in initial indications.

• Addresses high unmet need in later-line MM patients, with efficient regulatory and development paths.

• Combination with BCMA bispecifics (e.g., elranatamab) aims to improve depth of response and safety profile.

• Phase 2 MOMENTUM trial and Phase 1b combination trial are key milestones, with NDA submission targeted by end of 2028.

CFT8919 for NSCLC

• Oral, allosteric, mutant-selective EGFR L858R degrader designed to overcome resistance and improve tolerability compared to current inhibitors.

• Demonstrates activity in preclinical models, including those resistant to osimertinib and with brain metastasis.

• Fastest path to market is in 2L+ NSCLC, with potential expansion to front-line therapy.

• Large patient populations identified in the US, China, and EU4+UK, supporting significant market opportunity.